Novartis AG $NVS Stock Sold by Monte Financial Group LLC

Posted by on Nov 6th, 2026

Monte Financial Group LLC reduced its stake in Novartis AG (NYSE:NVS – Free Report) by 9.5% during the 3rd quarter, Holdings Channel.com reports. The firm owned 40,292 shares of the company’s stock after selling 4,243 shares during the period. Novartis accounts for 1.9% of Monte Financial Group LLC’s holdings, making the stock its 22nd largest holding. Monte Financial Group LLC’s holdings in Novartis were worth $5,744,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of NVS. Kestra Advisory Services LLC lifted its position in Novartis by 4.8% during the third quarter. Kestra Advisory Services LLC now owns 194,907 shares of the company’s stock worth $27,788,000 after acquiring an additional 9,001 shares during the last quarter. Claro Advisors Inc. boosted its holdings in shares of Novartis by 50.5% during the third quarter. Claro Advisors Inc. now owns 3,562 shares of the company’s stock worth $508,000 after acquiring an additional 1,196 shares during the period. Telos Capital Management Inc. grew its position in shares of Novartis by 1.0% in the third quarter. Telos Capital Management Inc. now owns 25,748 shares of the company’s stock valued at $3,671,000 after purchasing an additional 265 shares during the last quarter. Commonwealth Equity Services LLC grew its position in shares of Novartis by 2.7% in the third quarter. Commonwealth Equity Services LLC now owns 152,688 shares of the company’s stock valued at $21,769,000 after purchasing an additional 3,997 shares during the last quarter. Finally, Pathway Financial Advisers LLC acquired a new position in shares of Novartis in the third quarter valued at approximately $87,000. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

NVS has been the topic of a number of recent research reports. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Novartis in a research note on Wednesday, October 28th. Bank of America restated a “buy” rating on shares of Novartis in a research note on Tuesday, September 8th. Deutsche Bank Aktiengesellschaft lowered Novartis from a “hold” rating to a “sell” rating in a report on Friday, October 30th. Weiss Ratings reiterated a “buy (b)” rating on shares of Novartis in a research report on Thursday, October 22nd. Finally, UBS Group reiterated a “neutral” rating on shares of Novartis in a research report on Wednesday, October 28th. Six analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, Novartis presently has an average rating of “Hold” and a consensus target price of $152.25.

Check Out Our Latest Stock Analysis on Novartis

Novartis Price Performance

Novartis stock opened at $161.83 on Friday. The stock’s fifty day moving average price is $148.66 and its two-hundred day moving average price is $152.16. Novartis AG has a one year low of $123.24 and a one year high of $170.46. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.88 and a quick ratio of 0.70. The firm has a market cap of $308.79 billion, a PE ratio of 18.56, a price-to-earnings-growth ratio of 3.04 and a beta of 0.40.

Novartis (NYSE:NVS – Get Free Report) last released its earnings results on Tuesday, October 27th. The company reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.25 by $0.21. The firm had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.53 billion. Novartis had a return on equity of 41.04% and a net margin of 18.11%. The company’s revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the company posted $2.25 EPS. As a group, research analysts expect that Novartis AG will post 9.04 EPS for the current fiscal year.

Novartis Company Profile

(Free Report)

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company’s research and commercial activities span areas including cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kisqali, Kesimpta, Leqvio, Pluvicto and Scemblix.

Novartis serves patients and healthcare providers in markets around the world.

Featured Articles

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS – Free Report).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.